What did researchers learn from this trial?
This trial helped researchers learn more about how acalabrutinib affects people
with CLL when given with obinutuzumab, rituximab, or venetoclax.
Researchers look at the results of many trials to decide which treatments work
best and are safest. This summary shows only the main results from this one trial.
Other trials may provide new information or different results.
At the time this summary was made and approved by the sponsor, further clinical
trials with acalabrutinib were not planned.
15 | Clinical Trial Results